{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:21:18Z","timestamp":1791829278495,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajgponline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Geriatric Psychiatry"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jagp.2023.08.010","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T11:24:40Z","timestamp":1692617080000},"page":"117-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":194,"title":["The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Xinda","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jagp.2023.08.010_bib0001","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gutjnl-2015-310572","article-title":"GLP-1 based therapies: clinical implications for gastroenterologists","volume":"65","author":"Smits","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jagp.2023.08.010_bib0002","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dme.14042","article-title":"Prevalence of comorbid major depressive disorder in Type 2 diabetes: a meta-analysis of comparative and epidemiological studies","volume":"36","author":"Wang","year":"2019","journal-title":"Diabet Med"},{"key":"10.1016\/j.jagp.2023.08.010_bib0003","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3390\/ijms21186969","article-title":"Clinical evidence of antidepressant effects of insulin and anti-hyperglycemic agents and implications for the pathophysiology of depression-a literature review","volume":"21","author":"Woo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jagp.2023.08.010_bib0004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jagp.2023.08.010_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2202-13-33","article-title":"Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis","volume":"13","author":"Hunter","year":"2012","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.jagp.2023.08.010_bib0006","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jagp.2023.08.010_bib0007","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jagp.2023.08.010_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224236","article-title":"Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: an exploratory meta-analysis","volume":"14","author":"Zhu","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jagp.2023.08.010_bib0009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2015.11.021","article-title":"GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality","volume":"65","author":"Anderberg","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jagp.2023.08.010_bib0010","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jagp.2023.08.010_bib0011","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jagp.2023.08.010_bib0012","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","year":"2022"},{"key":"10.1016\/j.jagp.2023.08.010_bib0013","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jagp.2023.08.010_bib0014","unstructured":"Wells BS GA, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp Accessed March, 2023."},{"key":"10.1016\/j.jagp.2023.08.010_bib0015","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"Sterne","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jagp.2023.08.010_bib0016","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2337\/dc10-1119","article-title":"Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jagp.2023.08.010_bib0017","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1463-1326.2010.01196.x","article-title":"Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes","volume":"12","author":"Bode","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jagp.2023.08.010_bib0018","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1007\/s00125-014-3302-0","article-title":"Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)","volume":"57","author":"de Wit","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.jagp.2023.08.010_bib0019","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-8587(19)30157-3","article-title":"Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Miras","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jagp.2023.08.010_bib0020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1477-7525-11-217","article-title":"Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study","volume":"11","author":"Reaney","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jagp.2023.08.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2019.05.044","volume":"257","author":"Pozzi","year":"2019","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jagp.2023.08.010_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.psyneuen.2018.05.010","article-title":"Repositioning of diabetes treatments for depressive symptoms: a systematic review and meta-analysis of clinical trials","volume":"94","author":"Moulton","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.jagp.2023.08.010_bib0023","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jad.2022.04.156","article-title":"Investigating the pro-cognitive and anti-depressant efficacy of metformin: a systematic review and meta-analysis of randomised controlled trials","volume":"310","author":"Nibber","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jagp.2023.08.010_bib0024","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jagp.2023.08.010_bib0025","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/archpsyc.1997.01830220033006","article-title":"'Vascular depression' hypothesis","volume":"54","author":"Alexopoulos","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jagp.2023.08.010_bib0026","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1176\/ajp.154.4.497","article-title":"MRI-defined vascular depression","volume":"154","author":"Krishnan","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jagp.2023.08.010_bib0027","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-8587(19)30405-X","article-title":"Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression","volume":"8","author":"van Sloten","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jagp.2023.08.010_bib0028","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jagp.2023.08.010_bib0029","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdi.12420","article-title":"Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus","volume":"7","author":"Groeneveld","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jagp.2023.08.010_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2019.01.016","article-title":"Brain insulin resistance: a treatment target for cognitive impairment and anhedonia in depression","volume":"315","author":"Hamer","year":"2019","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jagp.2023.08.010_bib0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fpsyt.2019.00057","article-title":"Insulin resistance as a shared pathogenic mechanism between depression and Type 2 diabetes","volume":"10","author":"Lyra","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jagp.2023.08.010_bib0032","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/path.5056","article-title":"The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease","volume":"245","author":"Batista","year":"2018","journal-title":"J Pathol"}],"container-title":["The American Journal of Geriatric Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748123003949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1064748123003949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T04:36:04Z","timestamp":1761021364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1064748123003949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1064748123003949"],"URL":"https:\/\/doi.org\/10.1016\/j.jagp.2023.08.010","relation":{},"ISSN":["1064-7481"],"issn-type":[{"value":"1064-7481","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Geriatric Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jagp.2023.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of American Association for Geriatric Psychiatry.","name":"copyright","label":"Copyright"}]}}